Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. - Wikidata - awgldk - TriplyDB

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

http://www.wikidata.org/entity/Q30578618

about

HIV-1 prophylactic vaccines: state of the art Recent Advances in Lentiviral Vaccines for HIV-1 Infection Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens Approaches to preventative and therapeutic HIV vaccines Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?Immune correlates of vaccine protection against HIV-1 acquisition Bone Marrow Gene Therapy for HIV/AIDS A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine Designing synthetic vaccines for HIV Adenovirus vectors for gene therapy, vaccination and cancer gene therapy Recruitment by a geospatial networking application for research and practice: the New York City experience.Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques Progress in HIV-1 vaccine development.New concepts in HIV-1 vaccine development Recent developments in clinical trial designs for HIV vaccine research Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa Development of a prospective cohort of HIV Exposed Sero-Negative (HESN) individuals in Jos Nigeria.Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.Recent Insights into the HIV/AIDS Pandemic.Modeling HIV vaccine trials of the future.Current views on the potential for development of a HIV vaccine.Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials.A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.HIV-1 vaccines: challenges and new perspectives Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239 Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys.Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging.Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model.Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.Long-chain peer referral to recruit black MSM and black transgender women for an HIV vaccine efficacy trial.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.The influence of delivery vectors on HIV vaccine efficacy FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

P2860

Q26740042-932DD62F-6EE0-4042-A657-AC72D33CAE00 Q26742169-7D8F74FA-E013-4DAF-96D7-A20957B1FA16 Q26750912-B0C4F05E-6202-4A6B-86D4-DDF9308CC4EF Q26764851-45EF222F-802C-4ACF-A568-3219884A25DE Q26765043-E9F570F6-7E14-4931-AF71-5BA7B4E3A954 Q26778573-427E5F99-263A-4F99-AF1C-AB3D937468B0 Q26801765-5870667C-7924-4361-BFF9-23AA920B8208 Q26830360-A89F6F03-3927-4BE7-8F6F-D9021521B591 Q26862617-E79CC583-7CD0-4652-A5CE-5FE08586F4CA Q27001601-A71D2AA5-E945-4A94-88F3-8056C721EAD0 Q27313302-418C1564-4002-4053-B0FA-AECDF3576163 Q27318508-B3D635F1-BA3E-49DE-A312-8B7B043081FF Q27693849-245915F5-B9B6-440E-B5C0-2C1B13E2746C Q28067027-A465808A-4165-4F46-8D1D-4F718F1DFA0C Q28083514-E4F33D31-4952-4D7B-8A1E-2C4654755813 Q28552786-54C4A937-1A81-494D-AC8B-61571A148AE3 Q30151894-EE3B3605-DE7A-44DF-A2C8-EF734BD1BA64 Q30206105-C110F570-1D1F-4F3A-873B-4945AE5EF9C2 Q30234577-43D3F721-F41F-4AE0-8601-821338A3E034 Q30235024-D81034F4-EA54-4F47-A573-56CB308B1F99 Q30393307-D9AA722D-3C53-4BA1-8AAD-01448A28A292 Q30397595-9E106DEC-A5C8-467C-BC78-D7408C871AA9 Q30781853-511F5B1A-3C42-48C0-ADB9-4E2417AD8624 Q30934059-2B15E721-8F8C-48DE-84C8-8F5B2B10B354 Q33577972-8F240F7E-1C3E-44C0-BEA9-11F1922BE496 Q33611645-4B719C66-B325-4E16-A2C2-B663D0F283AA Q33742529-D89AE769-52B3-4727-A286-B38B30DB60B7 Q33744109-583B1B12-B41C-4D9A-918E-22FE6AC00CB7 Q33780980-A077DDB8-41FB-4409-91CF-507F7CA0EC39 Q33803963-17871B0C-CF4F-49BB-BAD1-A5500F4626D5 Q33820903-3A44A497-CA0B-4826-B930-4E3BA532299A Q33867299-06664E70-B6C5-4A3E-B3F6-961470D47F5D Q33875160-46475356-D9D0-40E7-A621-6389AFFAA9F4 Q33939974-BE183847-A607-48C2-8F56-F5DEB062D010 Q33977866-A2680DB2-C725-4484-BC71-6B90C3C72D75 Q33987449-377C97DF-DF54-4E31-8635-4D975E443EDF Q34057711-2857E77B-F0B9-4CFA-9B4A-561730C5D6D1 Q34059103-90206462-83A9-4A2C-9496-47540494ED62 Q34077543-72390AF6-E028-4662-BAE2-B018B32762E5 Q34117524-57D46FE1-FB24-4C0B-BD34-81A3C1E4A894

P2860

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

http://www.wikidata.org/entity/Q30578618

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

@ast

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

@en

type

label

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

@ast

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

@en

prefLabel

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

@ast

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

@en

P1433

Q30578618-8C187608-7F31-4D48-A482-B07DE7A20AC6

P1476

Q30578618-62009FF5-595C-4386-9E58-2EBB34E9A06A

P2093

Q30578618-00993662-3DEC-4757-8B13-1289B5A62E30

Q30578618-04C16CC8-21E7-481A-990D-C1406E1A3ED3

Q30578618-058BB17D-4B05-4F58-853A-C088FE8D9F60

Q30578618-0E12BC62-A964-4952-8FA3-648F8D94F715

Q30578618-12E8A666-A934-42DF-83B3-5B4AB434D45D

Q30578618-295B7827-E383-4A67-956A-8C5781381AEE

Q30578618-2D5300D6-5C45-47D5-B3F9-EBCC633F3F69

Q30578618-577721F8-C644-4D59-B81C-E1F9CDEC5A15

Q30578618-5E9C1D04-ACB4-46BC-9F9D-C7AA98158BD9

Q30578618-6020D618-505C-48AC-B285-95F2CDAB70D3

P2860

Q30578618-021A4069-6ED6-45BC-8984-09AFBED64F4D

Q30578618-072193A9-BEB7-4F09-8691-40205D52949E

Q30578618-146062A0-EBBB-435A-8727-D527807F3534

Q30578618-17BC4B98-D8CA-4BA5-A3B3-170AAB666220

Q30578618-1CC36F5E-E6D7-4352-8B05-5EE429153E8C

Q30578618-1D12BEFB-69FD-4554-AC9C-CEF2643E640C

Q30578618-1F856EA6-C21F-437D-98B5-B1380BE86FB1

Q30578618-1F915788-FE4C-4A9F-8D57-7EE463781CA9

Q30578618-1F9D8F91-3957-457B-896C-25705F002D42

Q30578618-2359E511-7D12-4600-A726-50A942D58A2E

P304

Q30578618-32273D23-F261-4561-90F3-97162E2CCBB7

P31

Q30578618-A0B25CFA-DB83-4906-AC1A-89EF1F4BF410

P356

Q30578618-E1B8F33D-18A6-4717-BC67-108A7C329385

P407

Q30578618-2A9BB3DC-C70F-4685-B06D-26AA00B1B702

P433

Q30578618-4406431F-7C01-4433-9323-899797548615

P478

Q30578618-6EA1839F-21B7-4E38-B89D-E4176568E701

P50

Q30578618-0081D4CC-3782-421C-8E3C-578696651C3D

Q30578618-021B7D4A-6F75-4634-B27F-1279B6DFD9A8

Q30578618-06C4E3FF-6FD1-4188-A657-047730C9FFCA

Q30578618-40918FDB-8938-4AF4-8F40-4B304B552C65

Q30578618-8287AF79-4A13-4937-93DB-D8696E2DFF16

Q30578618-A257110A-B52C-49A8-9C78-885764B3CA77

Q30578618-B9DC1E7C-517B-4573-8E4D-04BB44349CA8

Q30578618-C517B5DD-C4B5-4EDF-B10C-12FB6D5A739A

Q30578618-D4F1FFEE-2F9B-463D-9A73-6520D915117A

Q30578618-ED0692FF-9C79-4160-9A91-C1E6404EE084

P577

Q30578618-6D2089A7-45F6-4B15-B22E-0DEF3F395B0D

P5875

Q30578618-B34E6ACF-7B87-4529-B6F8-1678A1AAE936

P698

Q30578618-3BC79191-6340-400E-ACA1-7C3CDE8B638D

P932

Q30578618-262B2DDC-BC14-402C-8B94-6D474027C0A8

P356

P1433

The New England Journal of Medicine

P1476

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

@en

P2093

Carter Bentley

http://www.w3.org/2001/XMLSchema#string

Chuka Anude

http://www.w3.org/2001/XMLSchema#string

Doug Grove

http://www.w3.org/2001/XMLSchema#string

Edwin DeJesus

http://www.w3.org/2001/XMLSchema#string

Elizabeth Adams

http://www.w3.org/2001/XMLSchema#string

Georgia D Tomaras

http://www.w3.org/2001/XMLSchema#string

HVTN 505 Study Team

http://www.w3.org/2001/XMLSchema#string

Ian Frank

http://www.w3.org/2001/XMLSchema#string

John Hural

http://www.w3.org/2001/XMLSchema#string

Mark J Mulligan

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Prevention of HIV-1 infection with early antiretroviral therapy

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

P304

2083-2092

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1310566

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

David C Montefiori

Magdalena E. Sobieszczyk

Barney S. Graham

P577

2013-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257529490

http://www.w3.org/2001/XMLSchema#string

P698

24099601

http://www.w3.org/2001/XMLSchema#string

P932

4030634

http://www.w3.org/2001/XMLSchema#string